Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes
Year: 2018
Type: article
Abstract: OBJECTIVE: We constructed a predictive model of long-term risk for severe hypoglycemia (SH: hypoglycemia requiring assistance) in patients with type 2 diabetes (T2DM). RESEARCH DESIGN AND METHODS: Data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (original n=10 251, n=5135 used in the current analysis), a randomized, multicenter, double 2×2 factorial design study examining the effect of glycemic, blood pressure, and lipid control on cardiovascular outcomes in patients with diagnosed T2DM, were used. Over the follow-up (3.76±1.12 years), the ACCORD participants experienced 607 incident SH events. Cox regression was used to identify the SH risk prediction model. RESULTS: We identified 17 predictors-glycemic management, age, race, education, waist circumference, medications (insulin, antihypertensive, HMG-CoA reductase inhibitors, sulfonylurea, biguanide and meglitinide), years since diabetes diagnosis, history of hypoglycemia in the last week, systolic blood pressure, diastolic blood pressure, serum creatinine, and urinary albumin creatinine ratio-to construct a prediction model for SH (c-statistic=0.782). Using this information, we derived point scores to estimate the 5-year risk for SH in individual patients with T2DM. After adjusting for other variables in the model, the three strongest predictors for SH over 5 years were intensive glycemic management (HR=2.37, 95% CI 1.99 to 2.83), insulin use (HR=2.14, 95% CI 1.77 to 2.59), and antihypertensive medication use (HR=1.90, 95% CI 1.26 to 2.86). CONCLUSION: Using the ACCORD data, we identified attributes to predict 5-year risk of SH in patients with T2DM, which warrant evaluation in broader populations to determine applicability.
Institution: University of Minnesota
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funders: Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Sanofi, University of Minnesota, Omron Healthcare, Bayer HealthCare, Novo Nordisk, National Institutes of Health, Centers for Disease Control and Prevention, National Institute on Aging, National Heart, Lung, and Blood Institute, National Eye Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS, ACCORD, ACCORD, G1955785366, G2121141810, G2150788371, G217652925, ACCORD, G2535401525, G2556935141, ACCORD, G3534128112, G3792726805, G401067667, ACCORD, G4931486092, G552090665, G604937562, G6535417321, G6920961921, G77894727, G781655334, G8499292716, PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS
OpenAlex ID: W2887823243
